Very important...ATL is applicable to all boys with DMD.
Sarepta's drug is only applicable to 13% of DMD boys.
Mark Diamond, CEO of Antisense Therapeutics said: “Given that there is currently no effective treatment for non-ambulant DMD patients, we are particularly encouraged by the preliminary data from the first six patients in this trial, which suggests a positive drug effect and may also demonstrate a meaningful slowing of disease progression compared to what might otherwise have been expected....
Lets all say it slowly: "...slowing of disease progression..."
.
Ann: Positive preliminary results from ATL1102 DMD Phase II trial, page-44
-
- There are more pages in this discussion • 552 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $47.27K | 463.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 319942 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 86442 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |